Trump Administration Tariff Negotiations and Tariff Measures
The tariff system is legally and operationally complex; headline rates alone do not establish the duty on any specific entry.
What changed
Canada's reported 50% duties became the most consequential newly active measure, while pharmaceutical measures remain preparatory.
Why it matters
Rates, exclusions, stacking and legal authority determine the actual burden on importers and households.
What to watch next
CBP notices, Federal Register schedules and court filings.
What we know
- Section 122 tariffs are temporary and statutorily constrained.
- Section 232 measures are product- and security-specific.
- Section 338 is being used in the Canada dispute.
- Proposed pharmaceutical tariffs are not equivalent to duties already collected.
Material unknowns
- Tariff stacking
- Exclusion eligibility
- Section 338 litigation
- Net customs revenue
U.S. strategic assessment
Critical interestThe tariff portfolio is broad but fragmented. Effective incidence depends on HTS treatment, exclusions, origin and importer behavior.
Objectives
- Revenue
- Reciprocity
- National security
- Onshoring
Strategy
- Country duties
- Sector duties
- Temporary global tariffs
- Exclusions and negotiated relief
Outcomes
- Duties are being collected under several authorities.
- Canada escalation demonstrates retaliation risk.
- No complete audited net-benefit account is available.
Risks
- Customs uncertainty
- Consumer price pass-through
- Input-cost shocks
- Retaliatory export losses
Sources
01Controlling legal notices
HTS and entry guidance
Proclamations
Independent tariff-policy reporting
Conservative policy assessment of tariffs and trade